Absence of FcεRI α Chain Results in Upregulation of FcγRIII-dependent Mast Cell Degranulation and Anaphylaxis

Evidence of Competition between FcεRI and FcγRIII for Limiting Amounts of FcR β and γ Chains

David Dombrowicz,* Véronique Flamand,* Ichiro Miyajima,† Jeffrey V. Ravetch,§ Stephen J. Galli,‖ and Jean-Pierre Kinet‡

* Molecular Allergy and Immunology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 20852; † Departments of Pathology, Beth Israel Deaconess Medical Center-East and Harvard Medical School, Boston, Massachusetts 02215; and ‡ Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York 10021

Abstract

In mouse mast cells, both FcεRI and FcγRIII are αβγ2 tetrameric complexes in which different α chains confer IgE or IgG ligand recognition while the signaling FcR β and γ chains are identical. We used primarily noninvasive techniques (changes in body temperature, dye extravasation) to assess systemic anaphylactic responses in nonanesthetized wild-type, FcεRI α chain −/− mice and Fcγ chain −/− mice. We confirm that systemic anaphylaxis in mice can be mediated largely through IgG1 and FcγRIII and we provide direct evidence that these responses reflect activation of FcγRIII rather than FcεRI. Furthermore, we show that FcγRIII-dependent responses are more intense in normal than in congenic mast cell–deficient KitW/Wv mice, indicating that FcγRIII responses have mast cell–dependent and –independent components. Finally, we demonstrate that the up-regulation of cell surface expression of FcγRIII seen in FcεRI α chain −/− mice corresponds to an increased association of FcγRIII α chains with FcR β and γ chains and is associated with enhanced FcγRIII-dependent mast cell degranulation and systemic anaphylactic responses. Therefore, the phenotype of the FcεRI α chain −/− mice suggests that expression of FcεRI and FcγRIII is limited by availability of the FcR β and γ chains and that, in normal mice, changes in the expression of one receptor (FcεRI) may influence the expression of functional responses dependent on the other (FcγRIII). (J. Clin. Invest. 1997. 99:915–925.) Key words: allergy • asthma • FcγRI • IgE • passive cutaneous anaphylaxis

Introduction

In the companion study (1), we showed that fatal active systemic anaphylaxis reactions to ovalbumin were expressed in normal mice, in genetically mast-cell–deficient KitW/KitWv mice, or in mice which lacked FcεRI because of targeted disruption of the gene encoding the FcεRI α chain (FcεRI α chain −/− mice, reference 2), but not in mice which lacked the FcRγ chain (FcR γ chain −/− mice, reference 3) that is common to FcεRI and FcγRIII, as well as FcεRI. We also found that FcεRI α chain −/− mice and mast cell–deficient KitW/KitWv mice, but not FcR γ chain −/− mice, could express fatal IgG1-dependent passive anaphylaxis responses. Taken together with the observation that IgG1 antibodies bind rather poorly to FcεRI (4), these findings strongly suggested that some of the cardiopulmonary changes, as well as the mortality, associated with active anaphylaxis in the mouse may be mediated by IgG1 antibodies and FcγRIII.

However, we also found that some of the changes in heart rate (HR) and/or pulmonary function which developed in association with active, or IgG1-dependent passive, systemic anaphylaxis were significantly greater in FcεRI α chain −/− mice than in wild-type (FcεRI α chain +/+ ) mice. The explanation for this observation was not immediately apparent. Extensive analysis of the cell and tissue distribution of the FcεRI α chain in mice indicates that it is expressed only in mast cells and basophils (2, 5), whereas the FcR γ chain common to FcεRI and FcγRIII is expressed in many additional cell types including macrophages, neutrophils, and natural killer cells (3, 6). Moreover, studies in in vitro–derived mouse mast cells indicate that, in the absence of the FcεRI α chain, mast cells can exhibit increased surface expression of FcγRII and/or FcγRIII (2).

Taken together, these findings raise the possibility that, in effector cells which ordinarily express FcεRI (i.e., mast cells and basophils), lack of the FcεRI α chain results in increased expression of FcγRIII and increased sensitivity of these cells to IgG1- and FcγRIII-dependent activation. This phenomenon would be expected to increase the intensity of the pathophysiological changes associated with FcγRIII-dependent systemic anaphylaxis. On the other hand, fatal active systemic anaphylactic responses associated with cardiopulmonary changes can be elicited in mice that genetically lack mast cells (1, 7–11). This finding would argue against an essential role for enhanced FcγRIII-dependent mast cell activation and mediator production as the mechanism to account for the increased intensity of active anaphylaxis in FcεRI α chain −/− versus +/+ mice.

We pursued the studies presented here to investigate three important issues regarding the pathogenesis of anaphylaxis in mice that were not fully resolved by the companion study (1). First, do FcR γ chain–dependent (and FcεRI-independent) anaphylactic reactions reflect the activation of FcγRI or FcγRIII? Second, does the increased intensity of certain physiological changes associated with anaphylaxis in FcεRI α chain

David Dombrowicz and Véronique Flamand contributed equally to this work.

Address correspondence to Dr. Jean-Pierre Kinet, Division of Experimental Pathology, Department of Pathology, Beth Israel Deaconess Medical Center-East, Research North, 330 Brookline Avenue, Boston, MA 02215. Phone: 617-667-1324; FAX: 617-667-3616.

Received for publication 3 June 1996 and accepted in revised form 12 December 1996.

The Journal of Clinical Investigation
Volume 99, Number 5, March 1997, 915–925

1. Abbreviations used in this paper: BMCMC, bone marrow–derived cultured mast cells; Cdyn, dynamic compliance; GL, lung conductance; HR, heart rate; KLH, keyhole limpet hemocyanin; PCA, passive cutaneous anaphylaxis.
--/-- versus wild-type mice reflect increased expression of FcγRIII on effector cells in the absence of the FcγRI α chain? Third, to what extent are the physiological changes associated with FcγRIII-dependent anaphylaxis mast cell–independent?

To investigate directly the role of FcγRIII-dependent effector cell activation in the development of anaphylactic reactions in FcγRI α chain --/-- or wild-type mice, we analyzed the responses elicited in these mice, and in genetically mast-cell-deficient WBB6F1-Kitw/Kitw+ mice (12–14), upon intravenous challenge with an antibody (2.4G2, reference 15) against the external domain of FcγRII/III. We also determined whether the increased surface expression of FcγRII and/or III on mast cells which lack the FcγRI α chain reflects increased association of the common FcR β and γ chains with mast cell FcγRIII in vitro. The results show that FcγRIII-dependent physiological responses, as well as FcγRIII-dependent mast cell activation, are significantly increased in FcγRI α chain --/-- versus wild-type mice, but that some of the physiological changes associated with these reactions clearly can occur by mast cell–independent mechanisms. The findings also suggest that availability of the common FcR β and γ chains may limit the surface expression, and, in turn, the function, of FcγRI or FcγRIII on effector cells involved in systemic anaphylactic responses.

**Methods**

**Animals**

FcγRI-deficient animals (FcγRI α chain --/-- mice) were produced by targeted disruption of the α subunit gene (2) and were then backcrossed for four generations with BALB/c mice. Heterozygous animals were then bred to obtain FcγRI α chain --/-- and +/+ (wild-type) animals with the same genetic background. Mice deficient for FcγRI, FcγRII, and FcγRIII, because of targeted disruption of the gene for the FcR γ subunit (FcR γ chain --/-- mice), have been described in detail (3). The FcR γ chain --/-- mice used for this study were F1 offspring of crosses between chimeras and C57BL/6 mice (3). Genetically mast-cell-deficient WBB6F1-Kitw/Kitw+ mice, which virtually lack tissue mast cells (12–14), and the congenic normal (WBB6F1-+/-+) mice were purchased from the Jackson Biological Laboratory (Bar Harbor, ME). Unless otherwise specified, mice were of either gender and were 8–16 wk old at the beginning of the experiments. In individual experiments, mice of approximately the same age (usually, within 2–4 wk) and size were used.

The animal experiments were conducted in accordance with the Beth Israel Hospital’s Institutional Animal Care and Use Committee and/or with guidelines prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (DHHS Publication No. 86-23, revised 1985). All mice were housed in microisolation cages in facilities supplied with high efficiency particulate-free air. Selected (“sentinel”) mice in each room were sampled quarterly (approximately every 3 mo) and were found to be disease-free based on microbiological, parasitological, serological, and pathological examination.

**ELISA for anti-DNP IgE or IgG antibodies**

96-well plates were coated overnight at 4°C with 2 μg/ml anti-mouse IgE (PharMingen, San Diego, CA) or 10 μg/ml anti-mouse IgG (Southern Biotechnology Associates, Birmingham, AL) in PBS, washed three times with PBS, and then saturated for 2 h at 37°C with 1% gelatin in PBS. All subsequent washes (six after each step) were performed with 0.05% (vol/vol) Tween 20 in PBS. Serial dilutions of samples and internal standards were performed in 0.1% gelatin in PBS and incubated overnight at 4°C. Detection of anti-DNP antibodies was performed using 125 ng/ml DNP-biotin (obtained by deactiva-

tion of DNP-bioyinin succinimidy ester) (Molecular Probes, Eugene, OR). Detection of IgE or IgG antibodies (for measurement of total IgE or IgG) was performed using a 1:2,000 dilution of goat anti–mouse IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) or a 1:500 dilution of goat anti–mouse IgE (Binding Site, Inc., San Diego, CA). Both antibodies were conjugated to alkaline phosphatase. Revelation of DNP-biotin was performed using horse-radish peroxidase-avidin and 3,3',5,5’-tetramethylbenzidine dihydrochloride (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD) as the chromogenic agent. Anti-DNP IgE (Sigma Chemical Co., St. Louis, MO) and anti-DNP IgG, (clone U 7.6) (a generous gift from Dr. R. Segal, Bethesda, MD) (16) were used as standards. The linearity range of the assays was typically 0.1–5 ng/ml for anti-DNP IgE and 1–50 ng/ml for anti-DNP IgG. Revelation of alkaline phosphatase–conjugated antibodies was performed using p-nitrophenylphosphate as substrate.

**Protocols**

**Sensitization for active systemic anaphylaxis to DNP-HSA.** Mice were sensitized according to the protocol of Flores-Romo et al. (17). Mice were injected intravenously with 300 ng of Bordetella pertussis toxin (Life Technologies, Gaithersburg, MD), then, 48 h later, they received an intraperitoneal injection of 375 or 630 μg of DNPg-keyhole limpet hemocyanin (KLH) (prepared by incubation of 20 mg/ml KLH with 20 mg/ml 2,4-dinitrobenzene sulfonic acid, sodium salt, and 20 mg/ml K2CO3) and 0.5% aluminium hydroxide (Reheis, Berkeley Heights, NJ) in PBS. Control animals were injected intraperitoneally with B. pertussis toxin and then intraperitoneally with 0.5% aluminium hydroxide without DNP-KLH. Blood samples were obtained by retroorbital puncture 20 d later for determination of serum concentrations of anti-DNP IgE or IgG. 24 h later, mice were injected intravenously with 1 mg DNPg-HSA (Sigma Chemical Co.) and 2% Evan’s blue dye (Aldrich Chemical Co., Milwaukee, WI) in PBS. To monitor changes in body temperature associated with anaphylaxis (18), rectal temperature was measured before antigen injection and for 40–70 min after antigen injection, using a rectal probe coupled to an analog thermometer (Yellow Springs Instrument Co., Yellow Springs, OH), as described (2). Animals that did not die from anaphylactic shock were killed 40–70 min after antigen challenge by cervical dislocation. For quantification of Evan’s blue dye extravasation, ears were removed, minced, and incubated at 80°C for 3 h in 2 ml of formamide; absorbance was read at 610 nm (19).

**Sensitization for IgG1-dependent passive systemic anaphylaxis.** Mouse monoclonal IgG1 anti-DNP antibodies (clone U7.6, as above, in amounts of 20–1,000 μg, either as a dilution of ascites in PBS or as protein A–Sepharose purified antibodies in PBS) were administered intravenously by tail vein in volumes of ~ 200 μl/mouse. Control mice received instead normal mouse IgG (Jackson ImmunoResearch Laboratories, Inc.) in PBS (~ 200 μl/mouse). 1 d (24 h) after injection of IgG1, anti-DNP or normal IgG, mice were injected intravenously with 1.0 mg DNPg-HSA and 2% Evan’s blue in PBS. Body temperature was monitored as described above.

**Anti-FcγRII/III antibody-induced anaphylaxis.** Alternatively, systemic anaphylaxis was induced by the intravenous injection of 100 μg of rat anti-FcγRII/III (2.4G2) antibodies (PharMingen) (15) in 200 μl of PBS. Control mice received an equivalent amount of normal rat IgG (Jackson ImmunoResearch Laboratories, Inc.).

**Passive cutaneous anaphylaxis (PCA).** We attempted to elicit PCA reactions, essentially as described previously (20), by intradermal injections (with a 30-gauge needle in volumes of 20 μl) into the dorsal surface of the ear) of 25 ng anti-DNP IgE in PBS in the left ear, and 1.5 μg anti-DNP IgG, in the right ear, followed 24 h later by intravenous injection of 100 μg DNP-HSA in 2% Evan’s blue in PBS. Control animals received the same intradermal dose of anti-Dansyl IgE (PharMingen) in the left ear and normal mouse IgG in the right ear. Quantification of Evan’s blue dye extravasation was performed 30 min after injection of antigen as described above.
Physiological measurements and histologic studies

In mice, anaphylactic responses can produce a striking diminution in body temperature (2), as well as cardiopulmonary changes. Furthermore, the temperature changes associated with systemic anaphylaxis can be monitored in mice which have been subjected to neither the general anesthesia nor the surgical manipulations that are required to prepare the mice for analysis of the cardiopulmonary changes which are associated with the response (21). Accordingly, in this study, we primarily used changes in body temperature, as well as assessment of death rates, to investigate the intensity of the various anaphylactic responses.

In one set of experiments, we assessed the cardiopulmonary changes and mast cell degranulation associated with 2.4G2 antibody-induced anaphylactic reactions in FcRI α chain −/− and +/+ mice. HR and the pulmonary mechanical parameters, dynamic compliance (Cdyn) and lung conductance (Gdyn), were measured (by I. Miyajima) in mice anesthetized with 70–90 mg/kg, i.p., of sodium pentobarbital using a plethysmographic method, as described in the companion study (1). HR, Cdyn, and Gdyn were measured at multiple intervals after intravenous injection, via an indwelling jugular vein catheter, of 100 μg of rat 2.4G2 antibody (or, as a control, 100 μg of normal rat IgG) admixed in sterile, pyrogen-free 0.9% NaCl, in a total volume of 100 μl, until death due to 2.4G2 challenge or, after a period of 60 min, cervical dislocation. Changes in HR, Cdyn, and Gdyn after injection of 2.4G2 antibody or normal rat IgG were expressed as percent change versus baseline values (1). The state of mast cell activation was assessed (by I. Miyajima) in 1-μm, Epon-embedded, Giemsa-stained sections, as described in the companion study (1, 22–24). Mast cells were classified as “extensively degranulated” (> 50% of the cytoplasmic granules exhibiting fusion, staining alterations, and/or extrusion from the cell), “moderately degranulated” (10–50% of the granules exhibiting fusion or discharge), or “normal” (10, 20, 23, 24).

Analysis of FcyRIII expression in bone marrow–derived cultured mast cells (BMCMCs)

BMCMCs were generated from FcRI α chain −/− and +/+ mice by culture of femoral bone marrow cells for 3 wk in the presence of IL-3 as described previously (2). For each sample, 1.5 × 10^7 cells were lysed with 1% digitonin in 150 mM NaCl and 50 mM Hepes, pH 7.4, for 30 min at 4°C at a concentration of 5.0 × 10^7 cells/ml. The cell lysates were centrifuged for 20 min at 4°C at 14,000 rpm. The supernatants were then immunoprecipitated with either 10 μg of 2.4G2 antibody or with 30 μl of a rabbit antiserum specific for FcRI β chain (25), whereas the section containing species with molecular masses > 21,000 D was probed with an monoclonal antibody specific for FcRI β chain (26), and the section containing species with molecular masses < 21,000 D was probed with an antiserum specific for FcRI γ chain (26).

Statistical analysis

Differences among the various groups of mice in the time courses of body temperature, HR, Cdyn, or Gdyn responses were examined for statistical significance by ANOVA. Differences in values for Evans’ blue dye extravasation into the skin, or in the maximum diminution in Cdyn or Gdyn, or the maximum HR responses, were examined by the Student’s t test (two-tailed). Differences in the extent of mast cell degranulation in various groups of mice were examined for statistical significance by the χ^2 test. Differences in the death rates between different experimental groups were examined for statistical significance by Fisher’s exact test. Differences in the serum levels of anti-DNP IgE or IgG antibodies in the different experimental groups in experiments assessing active anaphylaxis were examined for statistical significance by the Mann Whitney U test. P < 0.05 was regarded as significant. Unless otherwise specified, results are expressed as the mean±SEM.

Results and Discussion

Both FcRI α chain −/− mice and FcRI α chain +/+ (wild-type) mice exhibit active anaphylaxis to challenge with DNP-HSA. We first wished to confirm, using a different antigen and assessing levels of antigen-specific IgE and IgG antibodies, the finding that active systemic anaphylaxis can be expressed in the absence of the FcRI α chain (1). In Fig. 1 A, we show that both FcRI α chain −/− and FcRI α chain +/+ (wild-type) mice developed antigen- (DNP-) specific IgE and IgG antibodies after immunization with 375 μg of DNP-KLH.

![Figure 1](image-url)

**Figure 1.** (A) Serum levels of anti-DNP IgE or IgG antibodies in FcRI α chain −/− (white bars) or wild-type (black bars) mice 20 d after active immunization with 375 μg of DNP-KLH (DNP-KLH SENSITIZED) (mean±SD, n = 3 per group). (B) Extravasation of Evans’s blue dye (assessed by absorbance at 610 nm) into the ear skin of mice 30 min after intravenous challenge with 1.0 mg of DNP-HSA; responses in DNP-KLH–immunized (DNP-KLH SENSITIZED) wild-type mice (black bars) or FcRI α chain −/− mice (white bars) mice are significantly greater than those in sham-immunized (CONTROL) wild-type mice (striped bar). Data are shown as mean±SD (n = 3). *P < 0.03 by Student’s t test (two-tailed) versus data from sham-immunized mice.
The serum levels of IgE anti-DNP antibodies in wild-type mice (15.4 ± 8.7 ng/ml) were greater than those in the FcRRI α chain −/− mice (3.0 ± 3.2 ng/ml), but this difference was not statistically significant (P > 0.05 by the Mann-Whitney U test). Fig. 1 B shows that the same groups of three FcRRI α chain −/− and three wild-type mice also developed very similar levels of increased cutaneous vascular permeability upon intravenous challenge with 1.0 mg of DNP-HSA and 2% Evan’s blue dye (as assessed by quantification of the amount of Evan’s blue dye extravasated into the ear skin 60 min after antigen challenge).

We also analyzed serum IgE and IgG anti-DNP antibody levels in two additional groups of three FcRRI α chain −/− mice and three wild-type mice, one group after immunization with 375 μg of DNP-KLH and the other after immunization with 630 μg of DNP-KLH. These DNP-KLH–immunized mice also developed antigen-specific IgE and IgG antibodies, again without statistically significant differences between the values in FcRRI α chain −/− or wild-type mice (data not shown).

All three groups of DNP-KLH–immunized or sham-immunized FcRRI α chain −/− and wild-type mice were examined for changes in body temperature in response to intravenous challenge with 1.0 mg of DNP-HSA. The results for the three groups of actively immunized or sham-immunized mice of the same genotype were very similar, and therefore are presented together in Fig. 2. In comparison to the results obtained in antigen-challenged, nonsensitized control wild-type mice, both wild-type mice and FcRRI α chain −/− mice which had been immunized with DNP-KLH exhibited significant drops in body temperature upon antigen challenge (Fig. 2). The drop in body temperature was more pronounced in FcRRI α chain −/− mice than in the wild-type mice, but the difference did not achieve statistical significance by ANOVA. Antigen challenge resulted in the death of six of the nine wild-type mice and seven of the nine FcRRI α chain −/− mice, versus none of the eight unsensitized wild-type mice (P < 0.01 versus the death rate in sensitized mice of either genotype by Fisher’s exact test).

FcRRI α chain −/− mice exhibit a greater reduction in body temperature than wild-type mice in association with IgG2-dependent passive systemic anaphylaxis. The findings presented in Fig. 2 confirm, using a different antigen (DNP-KLH) and a different means of quantification (change in body temperature), the results presented in our companion study (1), which showed that active anaphylaxis responses to ovalbumin were at least as intense in FcRRI α chain −/− mice as in the wild-type (FcRRI α chain +/+ ) mice. Clearly, the responses to antigen challenge in actively immunized wild-type mice may have reflected the contributions of both IgE and IgG2 anti-DNP antibodies. By contrast, the available evidence strongly suggests that the responses in FcRRI α chain −/− mice had little or no IgE-dependent component. Thus, FcRRI α chain −/− mice exhibited no detectable enhancement of vascular permeability (as assessed by the extravasation of Evan’s blue dye) when challenged for expression of either IgE-dependent passive cutaneous or systemic anaphylaxis (2). Nor did they express detectable changes in HR, Cdyn, or Gs, significant mast cell degranulation, or death, in response to challenge for IgE-dependent systemic anaphylaxis (1).

Figure 2. Active systemic anaphylaxis is associated with a drop in body temperature in both FcRRI α chain +/+ (WILD TYPE) and FcRRI α chain −/− (FcRIα −/−) mice. DNP-KLH–immunized (DNP-KLH SENSITIZED) wild-type mice (filled squares, solid line, n = 9) and FcRRI α chain −/− mice (open squares, solid line, n = 9), and sham-immunized (CONTROL) wild-type mice (filled squares, dotted line, n = 8) were challenged with 1.0 mg of DNP-HSA, i.v., 20 d after immunization with DNP-KLH or sham immunization, and the body temperature was recorded at multiple intervals thereafter (see Methods). Data are presented as mean ± SD. *P < 0.04 by ANOVA versus data from sham-immunized wild-type mice. The data include results from the mice depicted in Fig. 1.

Figure 3. Cutaneous (ear skin) extravasation of Evan’s blue dye in mice of various genotypes in response to intravenous challenge with 100 μg of DNP-HSA in 2% Evan’s blue. Sites (ears) were injected intradermally 24 h earlier with 25 ng of mouse monoclonal IgE anti-DNP antibodies (white bars, right ears) or 1.5 μg of mouse monoclonal IgG2 anti-DNP antibodies (black bars, left ears), or, as controls, 25 ng of a mouse monoclonal IgE antibody of irrelevant antigenic specificity [IgE Control (right), vertically striped bar] or 1.5 μg of normal mouse IgG [IgG Control (left), horizontally striped bar]. Data are shown as mean ± SD (n = 3 per group). *P < 0.003 by Student’s t test (two-tailed) versus data from sites in wild-type mice injected with control IgE; †P < 0.004 versus data from sites in wild-type mice injected with IgE anti-DNP; #P < 0.02 versus data from sites in wild-type mice injected with control IgG.
Nevertheless, we cannot formally rule out some role for IgE in the active anaphylactic responses detected in FcγRI α chain −/− mice. IgE can interact with receptors other than FcγRI (e.g., FcγRII/III, reference 27) and it is possible that the patterns of expression of such receptors on various effector cells are altered as a consequence of the active immunization procedure. Therefore, we directly investigated whether IgG antibodies might contribute to the drop in temperature associated with systemic anaphylactic responses in mice. We first determined whether our monoclonal IgG anti-DNP antibodies could sensitize mice for the expression of PCA. As shown in Fig. 3, the monoclonal IgG anti-DNP antibodies conferred reactivity for PCA in wild-type mice or FcRI α chain −/− mice, but not in Fcγ chain −/− mice. By contrast, neither FcRI α chain −/− mice nor FcR γ chain −/− mice expressed IgE-dependent PCA responses (Fig. 3).

We then performed dose–response experiments in normal mice to assess the ability of our monoclonal IgG anti-DNP antibodies to sensitize mice for passive systemic anaphylaxis. As shown in Fig. 4, normal mice exhibited a drop in body temperature in response to challenge with 1.0 mg of DNP-HSA that was dependent on the dose of IgG anti-DNP antibodies which had been used for passive sensitization 1 d earlier. Maximal and virtually identical responses were elicited in mice which had received either 500 or 1,000 μg of IgG anti-DNP antibodies. We also compared the temperature responses in normal mice which had been injected with either 400 μg of purified IgG anti-DNP antibodies or 400 μg of IgG anti-DNP antibodies as a dilution of ascites, and we found that the responses were essentially identical (data not shown). In all of these experiments, none of the mice died upon antigen challenge.

We then passively sensitized FcγRI α chain −/− mice, FcR γ chain −/− mice, and wild-type mice with 400 μg of IgG anti-DNP (as a dilution of ascites) and, as a control, tested wild-type mice which had received 400 μg of normal mouse IgG. Upon challenge with 1.0 mg of DNP-HSA in 2% Evan's blue, both wild-type and FcγRI α chain −/− mice developed a significant drop in body temperature compared with the response in the control, normal IgG-injected, wild-type mice (Fig. 5). Moreover, the IgG-RI-dependent temperature reduction induced by antigen challenge in FcγRI α chain −/− mice was significantly greater (by ∼1.0°C at the maximal point of diminution, 50 min after antigen injection) than that in the identically sensitized and challenged wild-type mice (P < 0.0001 by ANOVA). By contrast, IgG1 anti-DNP antibody-injected FcR γ chain −/− mice exhibited no drop in temperature upon antigen challenge (Fig. 5).

Notably, in contrast to FcRI α chain −/− or wild-type mice which expressed active systemic anaphylaxis, neither the FcRI α chain −/− mice nor the wild-type mice which developed a drop in temperature in association with IgG1-dependent passive systemic anaphylaxis exhibited prominent cutaneous extravasation of Evan’s blue dye. Indeed, by visual inspection, it was not possible to detect differences in the Evan’s blue dye extravasation in the ears of these mice as opposed to those of control animals which received normal mouse IgG instead of IgG1 anti-DNP before challenge with DNP-HSA. We did not perform actual measurements of

Figure 4. Changes in body temperature in wild-type mice which received various amounts of mouse monoclonal IgG anti-DNP antibodies (IgG, Anti-DNP) intravenously (as shown) or, as a control, 200 μg of normal mouse IgG (IgG Control, filled circles, dotted line), and then 24 h later, were challenged intravenously with 1.0 mg of DNP-HSA. Data are shown as the mean±SD (n = 3 per group). *P < 0.05, ***P < 0.001 by ANOVA versus data from control mice injected with 200 μg of normal mouse IgG.

Figure 5. Changes in body temperature after intravenous challenge with 1.0 mg of DNP-HSA, administered 24 h after passive sensitization intravenously with 400 μg of mouse monoclonal IgG1 anti-DNP antibodies (IgG1 Anti-DNP), in wild-type mice (WILD TYPE, filled squares, solid line, n = 23), FcγRI α chain −/− mice (FcγRI α chain −/−, open squares, solid line, n = 23), and FcR γ chain −/− mice (FcR γ chain −/−, open triangles, solid line, n = 3), or administered 24 h after sham passive sensitization of wild-type mice by intravenous injection of 400 μg of normal mouse IgG (IgG Control, solid squares, dotted lines, n = 15). Data are shown as mean±SD. ***P < 0.0001 by ANOVA versus data from sham-immunized wild-type mice; †††P < 0.0001 by ANOVA versus data from IgG1 anti-DNP-immunized wild-type mice.
Evans’s blue dye extravasation in these experiments, however, and it is possible that our visual inspection failed to detect small differences in the dye extravasation in the ear skin of control animals versus mice treated to express IgG<sub>1</sub>-dependent passive systemic anaphylaxis. Nevertheless, our findings are fully consistent with results presented in the companion study (1), which showed that the cardiopulmonary changes associated with IgG<sub>1</sub>-dependent passive systemic anaphylaxis can occur even in the absence of histologic evidence of substantial cutaneous mast cell degranulation.

Fc<sub>RI</sub>α chain −/− mice exhibit anaphylactic responses to challenge with 2.4G2 anti-FcγRII/III antibodies that are more intense than those in wild-type mice. The FcR γ chain is expressed in both FcγRI and FcγRIII, as well as in FcγRI. Although IgG<sub>1</sub> antibodies bind more weakly to FcγRI than to FcγRIII, we wished to investigate whether anaphylactic reactions could be elicited by the direct triggering of FcγRIII, using an approach that does not activate FcγRI. Therefore, we injected mice intravenously with either 100 μg of 2.4G2, a rat monoclonal antibody specific for mouse FcγRII/III, or, as control, the same amount of normal rat IgG. As shown in Fig. 6, injection of 2.4G2 produced a significant drop in temperature in wild-type mice and FcγRI α chain −/− mice, but not in FcγR γ chain −/− mice. Moreover, the temperature reduction in the FcγRI α chain −/− mice was significantly greater than that in the wild-type mouse (P < 0.0003 by ANOVA).

In the companion study (1), we showed that FcγRI α chain −/− mice developed significantly more pronounced reductions in pulmonary G<sub>L</sub> and pulmonary C<sub>qeq</sub> during active systemic anaphylaxis than did the identically sensitized and challenged wild-type mice. We also found that FcγRI α chain −/− mice developed a more pronounced increase in HR, as well as a significantly greater drop in G<sub>L</sub>, in association with IgG<sub>1</sub>-dependent passive systemic anaphylaxis than did the identically challenged wild-type mice (1). In light of these findings, as well as the results shown in Fig. 6, we evaluated whether the cardiopulmonary changes associated with 2.4G2 antibody-induced anaphylaxis might be greater in FcγRI α chain −/− mice than in wild-type mice.

As shown in Fig. 6, the reduction in G<sub>L</sub> induced by 2.4G2 challenge in FcγRI α chain −/− mice was significantly greater than that in the identically challenged wild-type mice, with maximum drops versus baseline (at 5 min after 2.4G2 injection) of 17.2 ± 3.8% in FcγRI α chain −/− mice versus 6.8 ± 1.8% in wild-type mice (P < 0.05 by Student’s t test, two-tailed). Challenge of FcγRI α chain −/− mice with 2.4G2 induced an increase in HR (to a maximum of 19.7 ± 8.8%) over baseline at 5 min after 2.4G2 injection) that was significant at the P < 0.01 level when compared with the responses in control IgG-injected FcγRI α chain −/− mice, whereas the tachycardia response in the 2.4G2-injected wild-type mice (which reached a maximum of 12.6 ± 9.4% over baseline at 5 min after 2.4G2 injection) was significant only at the P < 0.06 level compared with the responses in control IgG-injected wild-type mice. As shown in Table I, challenge with 2.4G2 resulted in the death of all of the wild-type and FcγRI α chain −/− mice tested, whereas none of the mice injected with control IgG died. Death due to 2.4G2 injection tended to occur more rapidly in FcγRI α chain −/− mice than in wild-type mice, with death recorded at 35 min or less after 2.4G2 challenge in four of the six FcγRI α chain −/− mice versus only one of the five wild-type mice.

Notably, the kinetics of the tachycardia response to 2.4G2 injection, as well as the rapid and (in α chain −/− mice) partially reversible early component of the 2.4G2-induced reduction in G<sub>L</sub>, more closely resembled the responses observed in active systemic anaphylaxis, or IgE-induced passive systemic anaphylaxis, rather than those seen in IgG<sub>1</sub>-induced passive systemic anaphylaxis (compare Fig. 7 to Figs. 1, 3, and 5 in the companion study [1]). In the companion study (1), we found

Table I. Death Rates and Times until Death in Wild-Type (FcγRI α chain +/+) or FcγRI α Chain −/− Mice Injected Intravenously with Rat 2.4G2 Antibody or, as a Control, Normal Rat IgG

| Mice* | Injection | Death rates | Times until death
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>min</td>
<td></td>
</tr>
<tr>
<td>FcγRI α chain −/−</td>
<td>2.4G2</td>
<td>6/6†</td>
<td>30, 30, 35, 35, 45, 55</td>
</tr>
<tr>
<td></td>
<td>Normal IgG</td>
<td>0/5</td>
<td>DNA</td>
</tr>
<tr>
<td>Wild-type</td>
<td>2.4G2</td>
<td>5/5*</td>
<td>30, 40, 40, 50, 50</td>
</tr>
<tr>
<td></td>
<td>Normal IgG</td>
<td>0/5</td>
<td>DNA</td>
</tr>
</tbody>
</table>

*In this experiment, female mice of 20–29 g body weight were tested, with mean body weights in the four groups (experimental and control groups of two genotypes) varying by a maximum of 21%. DNA, does not apply. †P < 0.01 by Fisher’s exact test vs. values from normal IgG-injected (control) mice of the same genotype.
that active, or IgE-induced passive, systemic anaphylactic responses were associated with more extensive mast cell degranulation than was observed in the IgG₃-dependent passive systemic anaphylaxis responses. When tissues from the mice shown in Fig. 7 were analyzed histologically, we found that the extent of mast cell degranulation in the tissues of 2.4G2 antibody–injected FcRII chain mice significantly exceeded that detected in the tissues of wild-type mice which had been injected intravenously with 100 μg of rat 2.4G2 antibodies (2.4G2, solid lines) or 100 μg of normal rat IgG (Normal IgG, dotted lines). In groups in which some mice died before the end of the 60-min period of observation, mean values were determined based on data for the surviving mice. For clarity, only mean values are shown. At all intervals in all groups, the SEM for measurements of Cdyn or Gdyn were always <6% of the mean and measurements of HR were always <13% of the mean. *P < 0.07 and †P < 0.09 by ANOVA over the first 35 min of the response, and **P < 0.06 and ***P < 0.01 by ANOVA over the first 20 min of the response, versus data from normal rat IgG–injected (control) mice of the same genotype. ‡P < 0.05 by ANOVA over the first 20 min of the response versus data from 2.4G2 antibody–injected wild-type mice.

Taken together, these findings suggest that, under the conditions of our experiments, the cross-linking of FcRIII by 2.4G2 may represent a stronger trigger for the production of bioactive mediators by effector cells than activation of the cells via IgG₃ anti-DNP–DNP-HSA immune complexes. The results are also consistent with the possibility that mast cell activation can contribute to the intensity and/or kinetics of some of the pathophysiological changes associated with systemic anaphylactic responses, even though mast cells clearly are not required for the expression of the reactions. The more rapid development of physiological changes in 2.4G2 antibody–dependent, versus IgG₃ and antigen-dependent, responses may reflect the difference in the mechanisms of FcRIII cross-linking in these two models: 2.4G2 antibodies directly induce receptor cross-linking, whereas IgG₃ must first form immune complexes with antigen and then bind to, and induce cross-linking of, FcγRIII.

WBB6F₁+/+ normal mice exhibit anaphylactic responses to challenge with 2.4G2 antibodies that are more intense than those in genetically mast cell–deficient WBB6F₁-Kit⁺⁻/Kit⁺⁻ mice. To investigate further a possible role for mast cells in FcγRIII-dependent responses, we analyzed the reactions in mice that are virtually devoid of tissue mast cells (WBB6F₁-Kit⁺⁻/Kit⁺⁻ mice) and the congenic normal (+/+ ) mice (12–
study, which showed that stands in contrast to the results obtained in our companion systemic anaphylaxis. These findings indicate that while mast all of the Fc cell degranulation. On the other hand, we found that virtually likely than nonanesthetized mice to die as a result of IgG mice, such as those used in the companion study (1), are more than the congenic +/+ (wild-type) mice to both the cardiopulmonary changes and the mortality associated with passive systemic anaphylactic reactions that were induced by challenge with the same amounts of IgG3 and specific antigen as used in the present study (1).

One possible explanation for this discrepancy is that anesthetized, surgically manipulated, and artificially ventilated, as shown in Fig. 9 A, KιW/KιW+ mice and the congenic normal mice exhibited statistically indistinguishable drops in body temperature after passive sensitization with 400 μg of monoclonal IgG3 anti-DNP antibodies and intravenous challenge 1 d later with 1.0 mg of DNP-HSA. By contrast, only the +/+ mice exhibited a drop in body temperature in response to passive sensitization with IgE anti-DNP antibodies and challenge with DNP-HSA (Fig. 9 A). None of the mice in this experiment died as a result of IgG3- or IgE-dependent passive systemic anaphylaxis. These findings indicate that while mast cells may have been essential for the development of IgE-dependent passive anaphylaxis, mast cells made no detectable contribution to the magnitude of the drop in body temperature associated with the IgG3-dependent responses. This finding stands in contrast to the results obtained in our companion study, which showed that KιW/KιW+ mice were significantly less susceptible than the congenic +/+ (wild-type) mice to both the cardiopulmonary changes and the mortality associated with passive systemic anaphylactic reactions that were induced by challenge with the same amounts of IgG3 and specific antigen as used in the present study (1).

One possible explanation for why challenge with 2.4G2 antibodies produced more intense physiological and mast cell degranulation responses in FcRI α chain −/− mice than in FcRI α chain +/+ mice would be that mast cells in FcRI α chain −/− mice exhibit increased expression of FcyRIII.

Whatever the reason(s) for the differences in the mortality associated with IgG3-dependent passive systemic anaphylaxis in this and the companion study (1), our analysis of FcRI α chain −/− mice indicated that intravenous challenge with 2.4G2 antibodies produced significantly more mast cell degranulation, as well as more striking cardiopulmonary changes, than did challenge with IgG3 and specific antigen. Therefore, we compared the responses to intravenous challenge with 2.4G2 antibodies in normal (+/-) and genetically mast cell–deficient (KιW/KιW+ mice). We found that KιW/KιW+ mice exhibited a drop in body temperature in response to 2.4G2 challenge, but that the magnitude of this response was significantly less than that in the congenic normal (+/+ mice) (P < 0.0001 by ANOVA) (Fig. 9 B). Moreover, death occurred in 5 of the 12 WBB6F1−/+ mice challenged with 2.4G2 antibodies, but in none of the 6 identically challenged KιW/KιW+ mice (P = 0.09 by Fisher’s exact test). These findings show that while 2.4G2 antibody–induced anaphylactic responses can occur in the virtual absence of mast cells, the responses in KιW/KιW+ mast cell–deficient mice are significantly attenuated compared with those in normal mice. By contrast, FcR γ chain −/− mice were unresponsive to challenge with 2.4G2 antibodies (Fig. 9 B).

**Figure 8.** Extent of activation of mast cell populations in the ear skin, peribronchial tissues, or forestomach in rat 2.4G2 antibody–injected (2.4G2) or normal rat IgG3–injected (Normal IgG3) FcRI α chain −/− (FcRI α −/−) with corresponding wild-type (WILD TYPE) mice. 1-μm-thick, Epon-embedded, Giemsa-stained sections were examined as described in the text to assess the extent of mast cell activation in the tissues. Data, which are expressed as mean ± SEM, are from the same mice shown in Fig. 7. *P < 0.05, **P < 0.005, ***P < 0.001 by the χ² test versus data from the same anatomic site in normal rat IgG3–injected (control) mice of the same genotype. †††P < 0.001 by the χ² test versus data from the same anatomic site in corresponding 2.4G2-injected wild-type mice.
Figure 9. (A) Changes in body temperature after intravenous challenge with 1.0 mg of DNP-HSA administered 24 h after passive sensitization intravenously with 20 μg of mouse monoclonal IgE anti-DNP antibodies (IgE Anti-DNP), 400 μg of mouse monoclonal IgG anti-DNP antibodies (IgG, Anti-DNP), or 400 μg of normal mouse IgG (Normal IgG) in WBB6F1+/+ normal mice (WILD TYPE, filled symbols) or WBB6F1-KitWv/KitWv mast cell–deficient mice (KitWv/KitWv, open symbols). Data are shown as mean±SD (n = 3 per group). ***P < 0.0001 by ANOVA versus data from mice of same genotype that received normal IgG or versus KitWv/KitWv mice that received IgE anti-DNP. (B) Changes in body temperature after intravenous injection of 100 μg of rat monoclonal 2.4G2 antibody (2.4G2, solid lines) or 100 μg of normal rat IgG (Normal IgG, dotted lines) in WBB6F1+/+ normal mice (WILD TYPE, filled squares), WBB6F1-KitWv/KitWv mast cell–deficient mice (KitWv/KitWv, open squares), or FcRγ chain −/− mice (FcγRγ −/−, open triangles). Data are shown as mean±SD except for KitWv/KitWv injected with normal rat IgG (n = 2), which are shown as the mean values. *P < 0.02, ***P < 0.0001 by ANOVA versus data from normal rat IgG–injected mice of the same genotype; †††P < 0.0001 by ANOVA versus data from +/+ mice that had been injected with 2.4G2 antibodies.

compared with those in the wild-type mice. Previously, we showed that BMCMCs of FcγRI α chain −/− mouse origin exhibited increased surface expression of FcγRII/III (as detected by binding of 2.4G2 antibodies) compared with wild-type BMCMCs (2). However, this experiment did not discriminate between levels of expression of the two FcγR (FcγRII and FcγRIII) that are detected by the 2.4G2 antibody, which recognizes the highly conserved extracellular domains of FcγRII/III (15). Therefore, we generated BMCMCs of FcγRI α chain −/− mouse and wild-type (FcγRI α chain +/+ ) mouse origin, and then used antibodies specific for FcγRII and FcγRIII, as well as 2.4G2, in an attempt to immunoprecipitate FcγR γ chains and FcγR β chains that might be associated with the cells’ FcγR.

As shown in Fig. 10, anti-FcγRIII or 2.4G2 antibodies, but not anti-FcγRII antibodies, precipitated β and FcγR γ chains from the BMCMCs. However, the amounts of β or FcγR γ chains precipitated from the FcγRI α chain −/− BMCMCs greatly exceeded those precipitated from the wild-type (+/+ ) BMCMCs. It has been reported that the FcγR β chain can associate with FcγRIIα, as well as FcγRI, in transfected cells (28). Our results now show that the FcγR β chain can also associate with FcγRIII in nontransfected, bone marrow–derived mast cells. The demonstration that FcγRI α chain −/− BMCMCs express increased amounts of FcγRIII in comparison with wild-type BMCMCs is consistent with other lines of evidence which show that FcγRIII expression is increased when FcγR γ chains and FcγR β chains are not incorporated into FcγRI and therefore are available for FcγRIII (2,6). Taken together with the recent observation that the β chain can increase the intensity of signal transduction via the FcγRI (29), these findings are compatible with at least two mechanisms by which lack of the FcγRI α chain could result in increased FcγRIII-dependent

Figure 10. BMCMCs of FcγRI α chain −/− mouse origin (−/−) express increased amounts of FcγR β chain (β) and FcγR γ chain (γ) in association with FcγRIII than do BMCMCs of FcγRI α chain +/+ (wild-type) mouse origin (+/+). Lysates of BMCMCs were immunoprecipitated with either a rat 2.4G2 antibody against FcγRIII (2.4G2), normal rat IgG (Control), or polyclonal rat antibodies specific for the cytoplasmic domains of FcγRII (Anti-FcγRII) or FcγRI (Anti-FcγRI). Samples run on an 8–16% polyacrylamide gel were transferred to a PVDF membrane which then was probed separately with a monoclonal antibody specific for FcγR β chain (β) and an antisera against FcγR γ chain (γ).
mast cell activation: increased expression of FcγRII on the cell surface and/or increased association of the β chain with FcγRII.

Conclusions. In this study, we have resolved three important questions concerning the pathogenesis of systemic anaphylaxis responses in mice. First, what is the relative importance of FcγRI versus FcγRII in FcR γ chain–dependent systemic anaphylactic reactions? Second, does increased surface expression of FcγRII on mast cells which lack the FcγRI α chain reflect increased association of the common FcR β and γ chains with FcγRII, and does this have pathophysiological significance in vivo? Third, to what extent are the pathophysiological changes in FcγRII-dependent systemic anaphylaxis mast cell–dependent? To address these issues, we used measurements of body temperature to detect and quantify systemic active or passive anaphylactic reactions, or responses to injections of an antibody against FcγRI/III, in nonanesthetized mice which were subjected to neither surgical manipulations nor artificial ventilation.

We found that FcγRI α chain −/− mice can express active systemic anaphylactic reactions, as well as IgG1-dependent passive systemic anaphylaxis. We also showed that the intensity of some of the physiological changes associated with responses to IgG1 and specific antigen or intravenous challenge with 2,4G2 anti-FcγRI/III antibodies was greater in FcγRI α chain −/− mice than in the wild-type animals. These observations thus confirm and extend those in our companion study, which showed that anesthetized, surgically manipulated, and artificially ventilated FcγRI α chain −/− mice challenged to express active or IgG1-dependent passive systemic anaphylaxis can develop changes in HR, Cdyn and G3 which are at least as large as, and in some cases greater than, those in the corresponding wild-type mice (1).

In addition, we found that the previously reported increased surface expression of FcγRII and/or III by mouse mast cells which lack the FcγRI α chain (2) reflects the increased association of the common FcR β and γ chains with FcγRII. This finding clearly may have in vivo relevance, in that the mast cell degranulation, as well as the pathophysiological changes, associated with responses to intravenous challenge with 2,4G2 antibodies was significantly greater in FcγRI α chain −/− mice than in wild-type mice. Although these observations were made by comparing the responses in FcγRI α chain −/− mice with those in the corresponding wild-type mice, the findings strongly suggest that the expression of FcγRI- or FcγRII-dependent effector cell function in normal mice may be significantly affected by the availability of limiting amounts of the common FcR β and/or γ chains. Thus, approaches which result in diminished expression of FcγRI α chain may result in enhanced FcγRII-dependent effector function.

Finally, we observed that the responses induced by 2,4G2 antibody challenge in normal (+/+) mice were significantly stronger than those observed in the congenic mast cell–deficient KitW/V Kit−/− mice. In other words, although FcγRII-dependent pathophysiological changes can occur in the virtual absence of mast cells, mast cells may contribute to the intensity of these reactions.

Thus, we have shown that the direct activation of FcγRII with 2,4G2 antibodies, by a mechanism that does not also activate FcγRI, can produce physiological changes that are very similar to those observed in active anaphylaxis. This finding in normal mice, when taken together with the results obtained in FcγRI α chain −/− mice, strongly supports the hypothesis that the death associated with active systemic anaphylaxis in the mouse, as well as the drop in body temperature and other physiological changes associated with the reaction, may largely reflect IgG1-dependent activation of FcγRII. Our findings also indicate that mast cell activation can contribute to the intensity of FcγRII-dependent responses, especially in FcγRI α chain −/− mice, but that other effector cells must have important roles in the pathogenesis of these reactions. Monocytes and macrophages represent attractive candidate additional effector cells in these settings, since only these cells and natural killer cells are known to express FcγRII in the mouse and since monocytes/macrophages represent potential sources of many biologically active mediators (3, 6).

Acknowledgments

We thank Dr. David M. Segal for the mouse monoclonal IgG1 (clone U7.6) antibodies, Dr. Mark Daëron for antibodies against mouse FcγRII or FcγRIII, Dr. Zhen-Sheng Wang for assistance with the histology, and Dr. Beverly H. Koller for helpful discussions.

This work was supported in part by United States Public Health Service grants CA/Al-72074 and AI/CA-23990 (to S.J. Galli), GM-53930 (to J.-P. Kinet), by National Institutes of Health grants to J.V. Ravetch, and by the Israel Israel Hospital Pathology Foundation. D. Dombrowicz is supported in part by a fellowship from the FNRS (Belgium).

References

How to cite this article